重组与血浆源性血管性血友病因子预防血管性血友病产后出血的比较
该回顾性观察研究比较了2017年2月1日至2018年1月31日在西宾夕法尼亚血友病中心接受重组或血浆源性血管性血友病因子治疗的血管性血友病孕妇的产后出血情况。共12次分娩,重组组与血浆源组各6例,产后出血总体发生率为25.0%(3/12),两组间无差异(2/6 vs 1/6,P=1.000),估计失血量亦无差异(685 vs 462 mL,P=.384)。
要点
- 血管性血友病孕妇产后出血总体发生率为25.0%(3/12)。
- 重组组与血浆源组产后出血频率无差异(2/6 vs 1/6,P=1.000)。
- 两组估计失血量无差异(685 vs 462 mL,P=.384),分娩方式间亦无差异。
核心结论
- 尽管使用了较高剂量(80 IU/kg)的重组或血浆源性血管性血友病因子,血管性血友病孕妇产后出血仍发生于四分之一的活产中。
- 未来需要开展试验以开发和评估预防血管性血友病产后出血的新策略。
研究设计与样本
- 回顾性观察研究,比较2017年2月1日至2018年1月31日在西宾夕法尼亚血友病中心接受重组或血浆源性血管性血友病因子治疗的血管性血友病孕妇的产后结局。
- 共纳入12次分娩,其中阴道分娩7次、剖宫产5次;重组组6例、血浆源组6例。
主要发现
- 产后出血发生于12次分娩中的3次(25.0%),重组组2/6 vs 血浆源组1/6,P=1.000。
- 估计失血量重组组685 mL vs 血浆源组462 mL,P=.384。
- 估计失血量按分娩方式比较:阴道分娩P=.722,剖宫产P=.531。
- 两组中位年龄32.0 vs 27.0岁(P=.075),出血评分3.0 vs 3.5(P=.734),孕前体重指数29.0 vs 29.2 kg/m2(P=.691)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
von Willebrand disease (VWD) is a congenital bleeding disorder characterized by deficient or defective von Willebrand factor (VWF). Among women with VWD, postpartum hemorrhage (PPH) is common. Treatment options at delivery include plasma-derived VWF (pdVWF) and recombinant VWF (rVWF). However, limited data are available regarding their efficacy. We conducted a retrospective observational study comparing PPH in women with VWD treated at the Hemophilia Center of Western Pennsylvania between 1 February 2017 and 31 January 2018 with either rVWF or pdVWF. We compared postpartum outcomes, including PPH frequency and estimated blood loss (EBL) at delivery. There were a total of 12 deliveries, 7 vaginal and 5 cesarean. At delivery and for 3 days postpartum, 6 women received 80 IU/kg of rVWF and 6 received 80 IU/kg of pdVWF, based on prepregnancy weight, insurance, and/or patient choice. Treatment groups had similar demographics, including median age (32.0 vs 27.0 years; P = .075), bleeding scores (3.0 vs 3.5; P = .734), and prepregnancy body mass index (29.0 vs 29.2 kg/m2; P = .691). PPH occurred in 3 (25.0%) of 12 deliveries, with no difference by treatment group (2 of 6 rVWF vs 1 of 6 pdVWF; P = 1.000) and no difference in EBL by treatment group (685 vs 462 mL; P = .384) or delivery type (vaginal, P = .722 vs cesarean, P = .531). In summary, PPH occurred in one-fourth of the deliveries in women with VWD, despite a higher dose (80 IU/kg) of rVWF or pdVWF. Future trials are needed to develop and assess novel strategies to prevent PPH in VWD.
引用
- Machin N, Ragni MV. Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease. Blood Adv. 2020. PMID: 32692849. doi:10.1182/bloodadvances.2020002046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。